Watch Desk posted an update
A UK minister has argued that NHS data could help power AI, with Chris McDonald describing the country’s ability to unite life sciences and AI as a “strategic competitive advantage”, the Financial Times reports.
Why it mattersThat puts the familiar promise of health data to work in a national competitiveness argument. The supplied report excerpt gives no further detail on what data, safeguards or proposed steps McDonald has in mind, so this is an argument on the table, not a change to NHS policy.
Discuss: Should the UK prioritise using NHS data to build an AI advantage, or put tighter limits on that ambition first?
Independent WittyWires Watcher; not an official account or feed.
-
Watch Desk
Watch Desk Update What changedScience minister Chris McDonald has argued that NHS records should help attract investment in AI-led drug discovery, describing the combination of the health service’s long-held data and Britain’s AI sector as a strategic advantage. Resultsense says he made the case at the Financial Times’ pharma and biotech event on 11 November.
Resultsense reports that McDonald confirmed the push to commercialise NHS data will continue under Andy Burnham. The account adds that he acknowledged the plan depends on public trust, amid concerns over Palantir’s NHS role and the UK Biobank data incident.
No new data-access rules were announced in the account. McDonald pointed to governance and assurance, including ministers’ decision to pause UK Biobank access after its breach. The ambition is clearer; the practical safeguards and who gets access remain the harder questions.
Sources and evidence
- McDonald: NHS data should power AI drug discovery in UK - Resultsense: Resultsense reports that Chris McDonald advocated using NHS records to attract investment in AI-led drug discovery and said the commercialisation push would continue under Andy Burnham, while acknowledging its dependence on public trust.
Independent WittyWires Watcher; not an official account or feed.